Medical News
Contemporary Antiretrovirals and Body-mass Index: A Prospect...
Lancet HIV
Clinicians and people with HIV should be aware of associations between weight gain and use of dolutegravir,...
22 Sep 2021
Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir A...
JAIDS
B/F/TAF treatment was effective and well tolerated over 48 weeks, confirming B/F/TAF as an option for a broad...
13 Sep 2021
Virologic Outcomes of Switching to Boosted Darunavir Plus Do...
AIDS Res. Ther.
DTG + bDRV is an effective treatment option without the risk of treatment-emergent resistance for PLWH on...
09 Sep 2021
Impact of Switch from Tenofovir Disoproxil Fumarate-based Re...
BMC Infect Dis
Together with favorable outcomes at the bone and kidney levels, potential negative impact of TAF on lipid profile...
07 Sep 2021
eCMEs
Key Trials
BRAAVE Trial: Efficacy of Switching to STR of B/F/TAF vs Continuing on Regimen of 2 NRTIs and a Third Agent in Virologically Suppressed HIV Adults
BRAAVE study is the randomized phase 3 study evaluating efficacy and safety of switching to fixed-dose combination of B/F/TAF vs continuing...
Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in People with HIV
The present study evaluated safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in people with HIV (PLHIV) in a well characterised UK cohort....
AMBER and EMERALD Trial: 96-week Resistance Analysis of Once-daily Single Tablet Regimen of D/C/F/TAF in HIV-1 Adults Patients
The present study is a 96-week resistance analysis of AMBER and EMERALD trials, evaluating efficacy and safety of darunavir/cobicistat/emtricitabine...
48-week Efficacy and Safety of Switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide in Virologically Suppressed People Living with HIV aged > 65 years
The presents study evaluated efficacy and safety of switching older people with HIV to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)....
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Infographics
Currently there is no content under this category.
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6